Jaehyuk Choi, M.D., Ph.D. Titles and Appointments Professor Endowed Title Scheryle Simmons Patigian Distinguished Chair in Cancer Immunobiology School Medical School Department Dermatology | Harold C. Simmons Comprehensive Cancer Center Graduate Programs Cancer Biology Biography Download Curriculum Vitae Jaehyuk Choi, M.D., Ph.D. is a Professor of Dermatology and of the Simmons Comprehensive Cancer Center at UTSW. He is the inaugural director of the Center for Cellular Therapies and Cancer Immunology. An NIH-funded physician scientist, Dr. Choi has contributed to our understanding of the cellular and genetic bases of cutaneous lymphomas, reporting the first or the largest series of cutaneous CD4+ (MF, Sezary, and ATL), CD8+, CD4-CD8-, gamma delta, and multiple B cell lymphomas (diffuse large B cell and follicular). These studies have been published in Nature, Nature Cancer, Blood, amongst other journals. Collectively, they have identified clinically actionable biomarkers and therapeutic targets. His work has been recognized with the NIH New Innovator Award, the Damon Runyon Clinical Investigator Award, and the Mark Foundation Emerging Leader Award amongst others. Education Harvard University, AB, June 1998, Biochemistry Summa Cum Laude Yale University, M.D., Ph.D., June 2006, Immunology, Alpha Omega Alpha, Cum Laude, M.D., Ph.D. Thesis of the Year Post Graduate Training Yale University School of Medicine, 2006-2010, Dermatology Residency Yale University School of Medicine, 2009-2015, Post-doctoral Fellow Publications Featured Publications Naturally occurring T cell mutations enhance engineered T cell therapies. Garcia J, Daniels J, Lee Y, Zhu I, Cheng K, Liu Q, Goodman D, Burnett C, Law C, Thienpont C, Alavi J, Azimi C, Montgomery G, Roybal KT, Choi J, Nature 2024 Feb 626 7999 626-634 PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. Wartewig T, Daniels J, Schulz M, Hameister E, Joshi A, Park J, Morrish E, Venkatasubramani AV, Cernilogar FM, van Heijster FHA, Hundshammer C, Schneider H, Konstantinidis F, Gabler JV, Klement C, Kurniawan H, Law C, Lee Y, Choi S, Guitart J, Forne I, Giustinani J, Müschen M, Jain S, Weinstock DM, Rad R, Ortonne N, Schilling F, Schotta G, Imhof A, Brenner D, Choi J, Ruland J, Nat Cancer 2023 Sep The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion. Zhao L, Hsiao T, Stonesifer C, Daniels J, Garcia-Saleem TJ, Choi J, Geskin L, Rook AH, Wood GS, J Invest Dermatol 2022 Dec 142 12 3253-3261.e4 Retrospective analysis of sepsis in cutaneous T-cell lymphoma reveals significantly greater risk for Black patients. Hooper MJ, Veon FL, Enriquez GL, Nguyen M, Grimes CB, LeWitt TM, Pang Y, Case S, Choi J, Guitart J, Burns MB, Zhou XA, J Am Acad Dermatol 2022 Oct Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma. Church C, Pulliam T, Longino N, Park SY, Smythe KS, Makarov V, Riaz N, Jing L, Amezquita R, Campbell JS, Gottardo R, Pierce RH, Choi J, Chan TA, Koelle DM, Nghiem P, J Immunother Cancer 2022 Sep 10 9 A single-cell transcriptional gradient in human cutaneous memory T cells restricts Th17/Tc17 identity. Cook CP, Taylor M, Liu Y, Schmidt R, Sedgewick A, Kim E, Hailer A, North JP, Harirchian P, Wang H, Kashem SW, Shou Y, McCalmont TC, Benz SC, Choi J, Purdom E, Marson A, Ramos SBV, Cheng JB, Cho RJ, Cell Rep Med 2022 Aug 3 8 100715 Cutaneous T-Cell-Rich Lymphoid Infiltrates After SARS-CoV-2 Vaccination. Hooper MJ, Veon FL, LeWitt TM, Chung C, Choi J, Zhou XA, Guitart J, JAMA Dermatol 2022 Jul Lifestyle, demographic and Skindex measures associated with cutaneous T-cell lymphoma: a single institution cohort study. Nguyen M, LeWitt T, Pang Y, Bagnowski K, Espinosa ML, Choi J, Guitart J, Liszewski W, Zhou XA, Arch Dermatol Res 2022 Jun Differences in Merkel cell carcinoma survival by site of primary presentation. Zaidi AJ, Choi J, Nardone B, Liszewski W, J Am Acad Dermatol 2022 May 86 5 1120-1123 Gut dysbiosis in cutaneous T-cell lymphoma is characterized by shifts in relative abundances of specific bacterial taxa and decreased diversity in more advanced disease. Hooper MJ, LeWitt TM, Pang Y, Veon FL, Chlipala GE, Feferman L, Green SJ, Sweeney D, Bagnowski KT, Burns MB, Seed PC, Choi J, Guitart J, Zhou XA, J Eur Acad Dermatol Venereol 2022 Apr Results 1-10 of 50 1 2 3 4 5 Next Last Honors & Awards Chicago Biomedical ConsortiumNovel Immunotherapies for Pancreatic Cancer (2023-2023) NIH T32 AwardNorthwestern University Postdoctoral Training Program in Cutaneous Biology (2023-2025) Department of Defense IDEA AwardElucidating the Biology of Aggressive Kinase Fusion-Driven Cutaneous T- Cell Lymphomas (2022-2025) Mark Foundation Emerging Leader AwardExploiting Naturally Occurring Mutations to Engineer Next-Generation T Cell Therapies (2022-2025) Leukemia Lymphoma Society ScholarValidating Genomic Biomarkers of Aggressive Subtypes of CTCL (2021-2025) NIH R01 AwardMechanisms of Lymphomagenesis of Skin Resident Gamma Delta T Cells. (2021-2025) V Foundation Immuno-Oncology Translational Program AwardIdentifying Mechanisms of Resistance to Immunotherapy for Merkel Cell Carcinoma. (2021-2024) American Cancer Society-Research Scholar GrantValidating Genomic Biomarkers of Aggressive Subtypes of CTCL (2020-2024) Doris Duke Charitable Foundation COVID Bridge AwardValidating Genomic Biomarkers of CTCL (2020-2020) Lefkofksy AwardDesigning Novel Cellular Therapies for Intractable Cutaneous Lymphomas (2020-2022) Doris Duke Data Sharing AwardIdentifying the genetic basis of altered T cell receptor signaling in CTCL (2019-2020) National Comprehensive Cancer Network FoundationGenomic Determinants of Responses to Immunotherapy in MCC (2019-2021) Skin Biology and Disease Research Core Pilot and Feasibility AwardIdentifying and Characterizing Skin-Resident T cells (2019-2021) Doris Duke Clinical Research MentorshipIdentifying NF-KB Targets in CTCL (2018-2019) Chicago Region Physical Sciences Oncology CenterDefining the molecular consequences of isochromosomes on chromosome segregation and gene transcription. (2017-2018) NIH DP2 New Innovator AwardIdentifying Mechanisms Underlying T Cell Diversity (2017-2022) Northwestern University Clinical and Translational Sciences InstituteIdentifying targetable gene mutations in CBCL (2017-2018) Chicago Biomedical ConsortiumNovel single-cell analyses of tumor-specific T cells in MCC (2016-2018) Damon Runyon Clinical Investigator AwardValidating Genomic Biomarkers of CTCL (2016-2021) Doris Duke Clinical ScientistIdentifying the genetic basis of altered T cell receptor signaling in CTCL (2016-2019) Leukemia Research FoundationIdentification of the Drivers of Disease Progression in CTCL (2016-2017) Skin Cancer FoundationDevelopment of CTCL-Seq (2016-2017) American Cancer Society- Institutional Research GrantTargeting CD28 Mutations in CTCL (2015-2017) NIH K08 AwardThe Role of ZEB1 Mutations in CTCL (2015-2020) Yale SPORE in Skin Cancer Career Development AwardForward Genetic Screen to Identify Genes that Confer Resistance in Melanoma (2012-2014) Dermatology Foundation Career Development AwardForward Genetic Screen to Identify Genes that Confer Resistance in Melanoma (2011-2014) American Skin Association Research GrantForward Genetic Screen for Tumor Suppressors in Mouse Skin Using PiggyBac (2010-2011) Dermatology Foundation Investigator Research FellowshipForward Genetic Screen for Tumor Suppressors in Mouse Skin Using PiggyBac (2010-2011) Professional Associations/Affiliations Dermatology Foundation Medical and Scientific Review Committee (2022-2025)
